MGC Pharmaceuticals Ltd (LON:MXC) (ASX:MXC) said it has submitted a patent application for its CimetrA medical product to the Slovenian Intellectual Property Office (SIPO).
CimetrA is designed to treat multiple ailments including viral infections with acute and chronic inflammation, COVID-19 and variants of influenza, autoimmune diseases, adverse events resulting from the various forms of cancer therapy, and the promotion of an immune response to bacterial, viral, fungal and parasitic infections.
